FDA Determines Regulatory Review Period for ABREVA Patent Extension

Summary

The Food and Drug Administration has published a notice determining the regulatory review period for ABREVA, a human drug product, in response to a patent extension application submitted to the Commissioner of Patents and Trademarks.